Japanese distributor of laboratory and medical equipment and consumables to research institutions and hospitals.
Japanese distributor of laboratory and medical equipment and consumables to research institutions and hospitals.
Sells from a large catalogue, in print and online, of lab and clinical supplies from many makers, so a lab can order thousands of small items from one source; its own-brand products carry better margins than resold goods. Japan is the core, with operations in China and elsewhere in Asia.
In one line: Japan's Fisher Scientific (lab supply distribution).
Moat: narrow (distribution, scale). Broad catalog and logistics network for lab supplies built over decades.
Headquarters: Tokyo, Japan · Founded: 1948 · Employees: 758
Size AS ONE (7476.T) is a Japan Health Care company (Medical Distributors) with a market value of $1.10B, the 700th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,517 on 18 Nov 2026.
Performance Over six months the shares gained 24.5%, against -3.7% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 9.8% over the last twelve months (peer median +5.0%); the operating margin is 11.7% (peer median 2.3%).
Valuation It trades at 18.4× forward earnings against a peer median of 15.3× (5th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.1 points above its cost of capital (6.6% WACC).
Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥117B | ¥111B | ¥104B | ¥95.5B | ¥91.4B |
| Revenue growth | — | +7% | +9% | +5% | — |
| Gross profit | ¥35.3B | ¥33.5B | ¥31.3B | ¥29.2B | ¥28.5B |
| EBITDA | ¥15.5B | ¥14.7B | ¥13.4B | ¥12.3B | ¥13.0B |
| Net income | ¥9.58B | ¥9.18B | ¥8.23B | ¥7.50B | ¥8.11B |
| Free cash flow | n/a | ¥4.42B | ¥8.11B | ¥5.55B | ¥6.40B |
| Capital expenditure | n/a | ¥2.75B | ¥1.79B | ¥1.58B | ¥1.15B |
| Total debt | ¥8.36B | ¥4.75B | ¥7.21B | ¥3.65B | ¥6.27B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| AS ONE 7476.T | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% |
| Ship Healthcare 3360.T | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7476.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.6% | -0.1% | 8th lowest of 21 |
| 6-month return | +24.5% | -3.7% | 6th highest of 21 |
| Distance from 52-week high | -6.0% | -20.2% | 2nd highest of 21 |
| Revenue growth (TTM) | +9.8% | +5.0% | 5th highest of 21 |
| Operating margin | 11.7% | 2.3% | highest of 21 |
| Forward P/E | 18.4× | 15.3× | 5th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 0.0% | -1.3% | 8th most demanding of 17 |
| Growth delivered (Del g) | +6.3% | +6.7% | 9th highest of 17 |
| Hurdle (Req g minus delivered) | -6.3 pp | -6.7 pp | 9th least demanding of 17 |
| ROIC minus cost of capital | +10.1 pp | +0.3 pp | 2nd highest of 21 |
| EV / EBITDA | 10.1× | n/a | — |
| Net debt / EBITDA | -1.2× | 1.6× | 4th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 18.4× | 0.0% | +6.3% |
| Shinva Medical Instrument 600587.SS | China | $1.10B | -10% | +6% | 5% | 13.4× | -6.9% | +1.2% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | n/a | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | n/a | -2.7% | +17.9% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | n/a | n/a | n/a |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 9.5× | -9.7% | +6.0% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 21.1× | -1.0% | +3.9% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 47.7× | 24.7% | +29.9% |
| Shanghai Haohai Biological Technology 6826.HK | Hong Kong | $897M | -24% | -5% | -2% | 7.7× | 17.0% | +12.4% |
| Ship Healthcare 3360.T | Japan | $1.38B | +19% | +6% | 3% | 14.6× | -14.5% | +7.6% |
| Redcare Pharmacy RDC.DE | Germany | $1.50B | +53% | +19% | 0% | n/a | n/a | n/a |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 15.3× | 5.3% | +8.1% |
| Toho 8129.T | Japan | $1.64B | -5% | +4% | 1% | 22.2× | -4.6% | +5.1% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 12.0× | -6.2% | +3.8% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | n/a | -1.6% | +1.0% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | n/a | 13.1% | +7.5% |
| Suzuken 9987.T | Japan | $2.36B | +8% | +5% | 1% | 15.8× | -10.4% | +3.2% |
| Hanmi Science 008930.KS | South Korea | $2.58B | +48% | +6% | 4% | n/a | 26.0% | +9.6% |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | n/a | 21.1% | -18.1% |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | n/a | n/a | n/a |
| Asker Healthcare ASKER.ST | Sweden | $2.69B | -14% | +12% | 7% | 24.8× | 4.7% | +12.7% |